登录

FireGen Closes ¥10M Series A+ Round of Financing, Developing Nucleic Acid Detection Devices for Rapid Diagnosis

作者: Mailman 2020-04-30 09:12
凡知医学
http://www.fgbiomed.com/
企业数据由 动脉橙 提供支持
快速诊断产品开发商 | D轮 | 运营中
中国-北京
2023-09-21
融资金额:RMB¥1亿
建创医疗成长基金
查看

According to VCBeat, FireGen Biomedicals ("FireGen") has completed its Series A + funding round of tens of millions yuan, with participation from Jiangsu Xinlingchuang Capital and Tianjin Kechuang Angel Capital. Proceeds of this round will be used to further accelerate the registration of several nucleic acid detection reagents and devices for rapid diagnosis.


FireGen is a global biomedical company, founded by a team of returned scientists with 30 years' experience in the world's top pharmaceutical companies. The company has built a new generation of R&D platform of nucleic acid reagents and devices for the serious diseases, and developed innovative gene sequencing kits, genetic detectors and chips to promote the rapid diagnosis of genes into the primary medical system. 


FireGen has set up a large R&D center and production base in Kunshan, China, and has branches in countries such as the United States, Australia, and cities including Beijing, Tianjin, Nanjing, Suzhou, Wuhan, and other places. In addition, the company has cooperated with more than 30 foreign distributors. 


Up to now, FireGen has provided products and services for thousands of hospitals, pharmaceutical companies, scientific research institutes, and gene testing companies all over the world. Its well-known clients include the Chinese Academy of Sciences, Peking Union Medical College Hospital, PLA General Hospital, Fosun Pharma, and so on.


Previously, FireGen has obtained investment from professional medical funds such as CCBI Health Care Growth Fund and Hairong Capital. Song Keqing, founder and chairman of FireGen, said, "the company holds more than 100 authorized intellectual property rights, with innovative technology to reach the international advanced level. We also have a high-specification GMP factory, while meeting the production standards of the CFDA, CE, and FDA. "


>>>>

About Jiangsu Xinlingchuang Capital


Jiangsu Xinlingchuang Capital is an investment platform for cutting-edge technology firms in the fields of intelligent manufacturing, big health, and new energy in Jiangsu, Zhejiang and Shanghai. It has abundant resources from government, capital and market in the Yangtze River Delta.


>>>>

About Tianjin Kechuang Angel Capital


Founded in 2006, Tianjin Kechuang Angel Capital is an investment platform under Tianjin Science and Technology Commission. It invests in science and technology projects with technological strength and potential influence of the high-tech industry and provides enterprises with funds, government projects, entrepreneurship guidance, and other services.

相关赛道 IVD
注:文中如果涉及企业数据,均由受访者向分析师提供并确认。
声明:动脉网所刊载内容之知识产权为动脉网及相关权利人专属所有或持有。转载请联系tg@vcbeat.net。

Mailman

医疗行业观察者

分享
动脉橙
以上数据来自动脉橙产业智库

我们以独创的在线数据库方式,为健康产业人士提供全方位和实时的市场资讯、行业数据和分析师见解。现已覆盖数字健康、医疗器械、生物医药等近500+细分赛道,涉及公司名单、招投标、投融资信息、头部企业动态等各类数据并持续更新。

点击 【申请试用】了解动脉橙产业智库更多内容。
精彩内容推荐

Xunminkang Biotechnology Snares ¥10M in Series A Round

AcornMed Closes on ¥100M Series A Round of Financing

Biotechnology Company Matridx Completes ¥100M Pre-A Round of Financing

TaiLai Biosciences Raised ¥10M in Pre-A Round of Financing

Mailman

共发表文章3245篇

最近内容
  • 知之甚少:调研885名投资人后,原来美国VC们这样做决策

    2023-03-20

  • 辉瑞想要收购Seagen只是开始,这才是2023年并购的两大趋势

    2023-03-05

  • 【融资】核药企业Ratio再融资2000万美元,和拜耳合作研究新前列腺癌放射性疗法

    2023-02-09

上一篇

Maiwei Biotech Raises ¥1.97B in Series A Funding Round

2020-04-30
下一篇

【首发】八年磨一剑,微光医疗国产OCT系统顺利获准上市

2020-04-30